On November 7, 2019 Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer and other indications, reported that the Company will host an R&D event in New York on Tuesday, November 19, 2019 from 12:00 – 3:30 PM EST (Press release, Pieris Pharmaceuticals, NOV 7, 2019, View Source [SID1234550597]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The R&D event will feature presentations from management and thought leaders in immuno-oncology and respiratory diseases, including:

Michael A. Curran, PhD, Associate Professor, Department of Immunology and Scientific Director, ORBIT Platform, The UT MD Anderson Cancer Center
Geoffrey Y. Ku, MD, Assistant Attending Physician and Head, Esophagogastric Section, Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering
Anuradha Ray, PhD, Professor of Medicine, Department of Immunology and UPMC Endowed Chair in Lung Immunology Medicine, University of Pittsburgh
Sally E. Wenzel, MD, Professor of Medicine, Department of Medicine; Chair, Department of Occupational & Environmental Health; Acting Director, Asthma Environmental Lung Health Institute and UPMC Endowed Chair of Translational Airway Biology, University of Pittsburgh
Presentations will include expert discussant perspectives on recently presented data for PRS-343 and PRS-060, emerging data from the ongoing PRS-343 combination trial with atezolizumab, and perspectives on how these drug candidates could best fit into the emerging landscapes of asthma and immuno-oncology.

The event will be accessible via a live webcast through this link beginning at 12:30 PM EST on November 19, 2019.

On November 7, 2019 Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that it will present at the Society for the Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 34th Annual Meeting in National Harbor, MD (Press release, Surface Oncology, NOV 7, 2019, View Source [SID1234550596]). The presentations will include posters highlighting preclinical data from three programs in the Company’s portfolio, SRF388 (targeting IL-27), SRF617 (targeting CD39) and SRF231 (targeting CD47).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Each therapeutic candidate at Surface provides a compelling and differentiated biological rationale as an anti-tumor agent, with SRF617 and SRF388 IND filings anticipated in the fourth quarter of 2019," said Vito Palombella, Ph.D., chief scientific officer of Surface Oncology. "As demonstrated in these preclinical data presentations, the Surface team performs world-class research that has given us unique insights into these important immunomodulatory pathways."

Selected details of preclinical data presented in the posters include:

Friday, November 8, 2019:

Poster #P805: SRF388, a first-in-class, fully human monoclonal antibody targeting IL-27, blocks the immunoregulatory effects of IL-27 in immune cells and demonstrates preclinical in vivo anti-tumor activity

SRF388 binds to the p28 subunit of IL-27 with high affinity, inhibits IL-27 from interacting with IL-27RA, and inhibits IL-27-induced STAT1 phosphorylation in cells.
By preventing IL-27 from interacting with IL-27RA, SRF388 inhibits IL-27-stimulated immunoregulatory receptor expression.
SRF388 blocks IL-27 inhibition of PD-1-mediated cytokine production.
SRF388 inhibits the growth of disseminated lung tumors in vivo.
Saturday, November 9, 2019:

Poster #P652: The fully human antibody SRF617 is a potent enzymatic inhibitor of CD39 with strong immunomodulatory activity

SRF617 inhibits the enzymatic activity of CD39 on cells.
By blocking CD39, SRF617 enhances total CD4 cell proliferation and dendritic cell maturation in the presence of exogenous ATP.
SRF617 inhibits CD39 enzymatic activity in tumors, reduces systemic adenosine levels, inhibits tumor growth and increases tumor associated macrophages in preclinical tumor models.
Combination of a murine surrogate of SRF617 with anti-PD-1 inhibition significantly increases survival versus anti-PD-1 inhibition alone, in a preclinical mouse tumor model.
Poster# P272: SRF231, a fully human high-affinity anti-CD47 antibody, exerts potent preclinical antitumor activity through engagement of the Fc receptor (FcR), CD32a

SRF231 delivers an activating signal to myeloid cells via interactions between the Fc region of SRF231 and CD32a expressed on myeloid cells.
SRF231 displays favorable preclinical characteristics with respect to receptor occupancy/tumor exposure/efficacy relationship.
The posters will be available to view on the Surface Oncology website, here.

Individuals wishing to attend the Surface R&D day on November 18th should contact [email protected].

On November 7, 2019 Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), reported that Dr. Henry Ji, Chairman and CEO, and members of Sorrento’s research team will participate in upcoming industry conferences in the 4th quarter 2019 (Press release, Sorrento Therapeutics, NOV 7, 2019, View Source [SID1234550549]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sorrento will provide new data on recent advances in allogeneic cellular therapy research, including but not limited to 3 clinical areas Sorrento has been focusing on:

original Dimeric Antigen Receptor DAR (proprietary) approach
non-viral gene editing knock-out knock-in KOKI (proprietary) technology
allogeneic manufacturing aiming at increasing capacity and reducing end-patient-costs
Examples from the CD38 and BCMA programs will illustrate current progress in key development areas.

Several scientific posters will be presented at the upcoming Society of Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) and American Society of Hematology (ASH) (Free ASH Whitepaper) conferences and will be available following the event.

Zhangjiang International Summit on Cell Therapy 2019

Date: November 14th
Time: 11:15 AM China Time
Location: Shanghai

Next-generation off-the-shelf CAR-T cell therapy
Keynote Speaker, Dr. Henry Ji

American Society of Hematology (ASH Scientific Conference)

Date: December 7th through 10th
Location: Orange County Convention Center (OCCC), Orlando, Fl

Development of an Allogeneic Anti-BCMA T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure. Poster and audio.

Development of a Genetically Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure. Poster and audio.

Preclinical characterization of an anti-CD38/CD3 T Cell- redirecting bispecific antibody. Poster and audio.

Preclinical Evaluation of Human Placental-Derived Allogeneic CD19 CAR-T Cells Against B Cell Malignancies. (Sorrento sourced technology presented by Celularity).

Development of CD38 CAR Engineered Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (PNK-CAR38) as Allogeneic Cancer Immunotherapy. (Sorrento sourced technology presented by Celularity).

Ex-vivo activity of immuno-therapeutic approaches targeting CD38 against Daratumumab-resistant multiple myeloma patient samples. (Collaborative work between Sorrento and Karolinska institute). Late breaking abstract submission.
ASH online (following scientific conference)

Preclinical Development of a BCMA Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy. Selected for inclusion in November supplemental issue of Blood and for ASH (Free ASH Whitepaper) online abstracts.

Preclinical Development of a CD38 Targeting Antibody-Drug Conjugate for Treatment of Hematological Malignancies. Selected for inclusion in November supplemental issue of Blood and for ASH (Free ASH Whitepaper) online abstracts.
Longwood Annual Winter Meeting at Harvard Medical School 2019

Date: December 10th
Time: 8:30 AM Eastern Time
Location: Harvard Medical School, Joseph B. Martin Conference Center, Boston, MA

Identifying Novel Technologies and Therapeutic Areas
Expert panel discussion with Dr. Henry Ji

On November 7, 2019 Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, reported its third quarter 2019 results (Press release, Targovax, NOV 7, 2019, View Source [SID1234550509]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET (details below).

HIGHLIGHTS FOR THE THIRD QUARTER 2019

Targovax announced data from part 1 of the ONCOS-102 trial in checkpoint inhibitor refractory advanced melanoma, showing validated clinical responses in three out of nine patients (33% ORR), including one patient with a complete response and immune activation in all nine patients
The expansion part of the phase I/II trial of ONCOS-102 in combination with the checkpoint inhibitor Imfinzi in patients with advanced peritoneal malignancies opened for enrollment as the dose escalation part of the trial concluded successfully
Targovax announced the opening of Oslo University Hospital as site for ONCOS-102 trial in melanoma
POST-PERIOD HIGHLIGHTS

In October, Targovax was selected for oral presentation at Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2019 Annual Meeting. The presentation will be given bv Dr. Alexander Shoushtari, Principal Investigator of ONCOS-102 trial in melanoma, Memorial Sloan Kettering Cancer Center, NYC
Øystein Soug, CEO commented: "Oncolytic viruses are increasingly recognized as an important future class of immune activators, and Targovax is well positioned as one of the leaders in this rapidly evolving field. Currently, our main focus is to deliver the expected data read-outs from our ongoing ONCOS-102 combination trials in 2020, which we hope will solidify Targovax position as a leader in the oncolytic virus space."

Presentation

The presentation will take place at 10:00 CET at:

Hotel Continental
Stortingsgaten 24/26
0117 Oslo

The presentation will also be webcast live and can be accessed here.

Reporting material

Targovax 3Q presentation

Targovax 3Q report

The quarterly report and presentation are also available at the website www.targovax.com.

On November 7, 2019 BerGenBio ASA (OSE:BGBIO), reported that it will announce its results for the third quarter on Tuesday 19 November 2019 (Press release, BerGenBio, NOV 7, 2019, View Source [SID1234550508]). A presentation by BerGenBio’s senior management team will take place at 10am CET at:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Arctic Securities
Haakon VIIs gate 5
Oslo

The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Financial Reports. A recording will be available shortly after the webcast has finished.

The results report and presentation will be available at www.bergenbio.com in the section: Investors/Financial Reports from 7:00 am CET the same day.